Corticobasal Degeneration (CBD) is a rare, progressive 4-repeat (4R) tauopathy characterized by asymmetric parkinsonism, apraxia, cortical sensory loss, and alien limb phenomena[@motor2024][@meg2024]. CBD represents a significantly underserved area in neurodegeneration R&D, with limited clinical trials but important scientific activity given its pathological overlap with [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP) and [Frontotemporal Dementia](/diseases/frontotemporal-dementia) (FTD).
Last updated: 2026-03-29 11:55 PT
Clinical Trial Pipeline
Active clinical trials in CBD include:
[NCT05822362](https://clinicaltrials.gov/study/NCT05822362): CBD/Alzheimer's Disease Prevention — investigates early intervention in CBD prodromal and at-risk populations
[NCT06014424](https://clinicaltrials.gov/study/NCT06014424): CBD and Alzheimer's Agitation — symptom management in CBD with behavioral interventions
Investment context: The tau field has seen significant investment spillover from the lecanemab and donanemab approvals in AD[@cummings2024]. Anti-tau antibodies in development for PSP are being evaluated for CBD given shared 4R tau pathology.
Investment Context
...
Investment Landscape: Corticobasal Degeneration
Overview
Corticobasal Degeneration (CBD) is a rare, progressive 4-repeat (4R) tauopathy characterized by asymmetric parkinsonism, apraxia, cortical sensory loss, and alien limb phenomena[@motor2024][@meg2024]. CBD represents a significantly underserved area in neurodegeneration R&D, with limited clinical trials but important scientific activity given its pathological overlap with [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP) and [Frontotemporal Dementia](/diseases/frontotemporal-dementia) (FTD).
Last updated: 2026-03-29 11:55 PT
Clinical Trial Pipeline
Active clinical trials in CBD include:
[NCT05822362](https://clinicaltrials.gov/study/NCT05822362): CBD/Alzheimer's Disease Prevention — investigates early intervention in CBD prodromal and at-risk populations
[NCT06014424](https://clinicaltrials.gov/study/NCT06014424): CBD and Alzheimer's Agitation — symptom management in CBD with behavioral interventions
Investment context: The tau field has seen significant investment spillover from the lecanemab and donanemab approvals in AD[@cummings2024]. Anti-tau antibodies in development for PSP are being evaluated for CBD given shared 4R tau pathology.
Investment Context
CBD has a unique position in the tauopathy investment landscape:
Tau overlap with PSP: Programs targeting 4R tau in PSP may expand to CBD
FTLD connection: Progranulin (GRN) and MAPT programs bridge CBD and FTD
Rare disease designation: FDA/EMA orphan designations may accelerate development
Diagnostic advances: Tau PET imaging and fluid biomarkers enable better patient selection
Key Investment Themes
Anti-tau antibodies: Multiple programs targeting aggregated tau across 4R tauopathies
GRN modulation: Progranulin replacement approaches for GRN-mutation carriers
Neuroinflammation targeting: Microglia modulation given neuroimmune component
Symptomatic management: Apraxia, dystonia, and cognitive impairment interventions
Emerging Investment Areas
Tau propagation inhibitors: Blocking intercellular tau spreading
Microglial modulation: TAM receptor inhibitors and other neuroimmune targets
Combination approaches: Anti-tau + anti-amyloid for cases with mixed pathology
Gene therapy: AAV-based delivery of tau-modulating constructs
Biomarker partnerships: Tau PET ligand development with Life Molecular Imaging, Celldex
Investment Outlook
Near-Term (1-3 Years)
Tau antibody Phase 2 readouts expected. Expansion of biomarker-driven enrollment criteria. Potential for repurposed ALS/AD programs in CBD.
Medium-Term (3-5 Years)
Gene therapy programs advancing to pivotal trials. ASO approaches for MAPT targeting entering Phase 2/3. Potential for first disease-modifying therapy approval in CBD.
Long-Term (5-10 Years)
Prevention trials in genetically identified at-risk populations. Precision medicine based on MAPT haplotype, GRN status, and co-pathology profiles. Disease-modifying therapies potentially approved.
[Cummings J, et al, Alzheimer's Disease Drug Development Pipeline: 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38427984/)
[Motor imagery brain-computer interface in corticobasal syndrome (2024)](https://doi.org/10.1007/s10072-024-09345-9)
[Spatiotemporal characteristics of neurophysiological changes in patients with four-repeat tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38226843/)
Reuters, Roche advances tau program in PSP and CBD (2025)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate